The Condition
Understanding Long COVID
Long COVID, clinically referred to as post-acute sequelae of SARS-CoV-2 (PASC), is a complex condition in which symptoms persist for weeks, months, or even years after the initial COVID-19 infection has resolved. The condition can affect individuals regardless of how mild or severe their acute illness was, and it has emerged as a significant public health challenge with widespread impact on quality of life, work capacity, and daily functioning.
The most commonly reported long COVID symptoms include persistent fatigue that does not improve with rest, cognitive difficulties often described as "brain fog" (problems with memory, concentration, and executive function), sleep disturbances, chronic pain in muscles and joints, exercise intolerance, shortness of breath, and headaches. Many patients experience multiple symptoms simultaneously, creating a complex clinical picture that can be difficult to address with any single intervention.
Researchers have proposed several mechanisms that may contribute to long COVID symptoms, including persistent microclots and microvascular damage, chronic inflammation, immune dysregulation, mitochondrial dysfunction, and neuroinflammation. These proposed mechanisms share a common thread: impaired oxygen delivery and utilization at the tissue level. This is why researchers have turned their attention to hyperbaric oxygen therapy as a potential supportive approach.
Standard treatments for long COVID remain limited, and many patients seek complementary approaches to manage their symptoms. The growing body of published research on HBOT for post-COVID conditions has generated interest among both clinicians and patients looking for evidence-based options to support recovery.
The Science
How HBOT May Support Long COVID Recovery
Hyperbaric oxygen therapy works by delivering concentrated oxygen under elevated pressure, dramatically increasing the amount of oxygen dissolved in blood plasma. Researchers believe several mechanisms may be relevant to long COVID recovery.
Enhanced Oxygen Delivery
Under hyperbaric conditions, oxygen dissolves directly into blood plasma at levels far beyond normal. This oxygen-rich plasma can reach tissues with damaged or compromised microvasculature, potentially bypassing the microvascular dysfunction that researchers believe contributes to long COVID symptoms.
Inflammation Reduction
Research suggests that HBOT may help modulate the inflammatory response by reducing pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6, while supporting anti-inflammatory mediators. Chronic inflammation is considered a key driver of persistent post-COVID symptoms, particularly neurological ones.
Neuroplasticity Support
The 2022 Scientific Reports trial found changes in brain activity and microstructure on imaging following HBOT. Researchers propose that increased cerebral oxygenation may support neuroplasticity and neural repair, potentially addressing the cognitive dysfunction experienced by many long COVID patients.
Tissue Repair
HBOT has been shown to stimulate angiogenesis (new blood vessel formation) and support collagen synthesis. These tissue repair mechanisms may be relevant for long COVID, where microvascular damage and tissue injury are thought to play a role in symptom persistence.
Mitochondrial Function
Mitochondria require oxygen to produce cellular energy (ATP). Researchers have proposed that mitochondrial dysfunction may contribute to the fatigue and exercise intolerance seen in long COVID. HBOT delivers increased oxygen to cells, which may support improved mitochondrial energy production.
Stem Cell Mobilization
Published research suggests that repeated HBOT sessions may stimulate the release of stem cells from bone marrow into circulation. These stem cells are involved in tissue repair and regeneration, which may be relevant to recovery from the widespread tissue effects of long COVID.
Published Evidence
What the Research Shows
The most rigorous study on HBOT for long COVID published to date is a 2022 randomized, double-blind, sham-controlled trial by Zilberman-Itskovich et al., published in the journal Scientific Reports (a Nature Portfolio journal). This study represents the gold standard of clinical research design and provides the strongest published evidence for HBOT in post-COVID conditions.
2022 Scientific Reports Randomized Controlled Trial
Zilberman-Itskovich et al., Scientific Reports, 2022
This randomized, double-blind, sham-controlled trial enrolled long COVID patients who had experienced persistent symptoms for at least three months after confirmed SARS-CoV-2 infection. Participants were randomized to receive either 40 sessions of HBOT at 2.0 ATA or sham treatment. The study used validated outcome measures and brain imaging to assess changes.
Key Findings
- The HBOT group showed statistically significant improvements in cognitive function, including attention, executive function, and information processing speed, compared to the sham group
- Participants receiving HBOT reported significant improvements in energy levels and reduced fatigue severity
- Sleep quality improved significantly in the HBOT group compared to the control group
- Pain scores showed meaningful improvement in the treatment group
- Brain MRI imaging revealed improvements in brain microstructure and cerebral blood flow patterns in HBOT-treated participants
Beyond this landmark trial, additional published studies and case series have explored HBOT for post-COVID conditions with encouraging results. Researchers at multiple institutions around the world have initiated clinical trials to further evaluate HBOT protocols for long COVID, reflecting growing interest in this approach within the medical research community.
It is important to note that while these results are promising, researchers emphasize the need for larger, multi-center trials to confirm and expand upon these findings. HBOT for long COVID is an active area of investigation, and clinical protocols continue to be refined as new data becomes available. Patients interested in HBOT for post-COVID symptoms should consult with a qualified healthcare provider familiar with both their condition and hyperbaric medicine.
Areas of Research
Symptoms Being Studied
Researchers are investigating how HBOT may address a range of persistent post-COVID symptoms. The following areas have been studied in published clinical research or are the subject of ongoing clinical trials.
Cognitive Function
The 2022 Scientific Reports RCT reported statistically significant improvements in attention, executive function, and information processing speed. Brain imaging revealed measurable changes in brain microstructure and blood flow following HBOT.
Fatigue and Energy
Persistent fatigue is one of the most debilitating long COVID symptoms. The 2022 RCT found significant improvement in energy levels and fatigue severity in the HBOT group compared to sham. Researchers propose that enhanced oxygen delivery may support mitochondrial energy production.
Sleep Quality
Sleep disturbances are common in long COVID patients and can compound other symptoms. The published RCT measured significant improvements in sleep quality among HBOT participants, potentially related to reduced neuroinflammation and improved cerebral oxygenation.
Pain
Chronic pain in muscles, joints, and other areas is a frequent long COVID complaint. The 2022 trial reported meaningful improvement in pain scores in the treatment group. HBOT may address underlying inflammatory and microvascular factors contributing to post-COVID pain.
Exercise Tolerance
Many long COVID patients experience reduced exercise capacity and post-exertional malaise. Researchers are studying whether improved tissue oxygenation and mitochondrial support through HBOT may help restore exercise tolerance over time.
Neuroinflammation
Neuroinflammation is thought to play a central role in long COVID brain fog and cognitive symptoms. Research suggests HBOT may reduce neuroinflammatory markers and support neural repair processes, as indicated by brain imaging changes observed in the published trial.
Chamber Solutions
OxyHealth Chambers for Home and Clinical Use
OxyHealth is the global leader in hyperbaric chamber manufacturing, offering both portable chambers for home wellness use and clinical chambers for medical facilities. Every OxyHealth chamber is FDA-cleared and built to the highest safety standards in the industry.
For Home Use
Portable Chambers
The Vitaeris 320 and Respiro 270 are FDA-cleared portable chambers designed for safe, daily home use at 1.3 ATA. Home chambers provide the convenience of consistent daily sessions without clinic visits. Many individuals incorporate mild hyperbaric therapy into their broader wellness and recovery routines.
For Clinics
Clinical Chambers
The Fortius 420 and Quamvis 320 are clinical-grade chambers capable of higher pressures, designed for medical facilities, integrative health centers, and rehabilitation clinics. Published research on HBOT for long COVID has primarily used clinical-level protocols, making these chambers well-suited for facilities offering evidence-based HBOT programs.
Safety and Quality
OxyHealth: The Safest Chambers Available
OxyHealth is the global leader in hyperbaric chamber manufacturing, with over 19,000 chambers delivered worldwide and more than 3,000 physicians trusting OxyHealth technology. Every chamber is built to the highest safety and quality standards in the industry.
FDA 510(k)-Cleared
All OxyHealth chambers are cleared by the U.S. Food and Drug Administration as Class II medical devices.
ASME PVHO-1
Built to the American Society of Mechanical Engineers pressure vessel standard for human occupancy.
ISO 13485 Certified
Manufactured under the international quality management standard for medical devices.
UL Listed
Electrical components are tested and certified by Underwriters Laboratories for safety compliance.
Frequently Asked Questions
HBOT for Long COVID FAQ
Long COVID, also referred to as post-acute sequelae of SARS-CoV-2 (PASC), describes a range of symptoms that persist for weeks, months, or longer after the initial COVID-19 infection has resolved. Common symptoms include fatigue, cognitive difficulties often called "brain fog," sleep disturbances, chronic pain, and exercise intolerance. The condition can affect people regardless of how severe their initial infection was. Researchers continue to study the prevalence and mechanisms of long COVID, and it remains an active area of clinical investigation worldwide.
HBOT delivers concentrated oxygen under pressure, increasing the amount of oxygen dissolved in blood plasma. Researchers hypothesize that this mechanism may support recovery from long COVID through several pathways: improving oxygen delivery to tissues that may have sustained microvascular damage, potentially reducing neuroinflammation associated with cognitive symptoms, and supporting cellular repair processes. A 2022 randomized controlled trial published in Scientific Reports (Zilberman-Itskovich et al.) found that participants receiving HBOT showed improvements in cognitive function, energy levels, sleep quality, and pain compared to a sham control group. While these results are promising, researchers note that additional large-scale trials are needed.
The most significant study to date is a 2022 randomized, double-blind, sham-controlled trial published in Scientific Reports by Zilberman-Itskovich et al. This study evaluated HBOT in patients with long COVID symptoms persisting for at least three months. Participants who received 40 HBOT sessions showed statistically significant improvements in cognitive function, energy, sleep, and pain compared to the sham group. Brain imaging also revealed improvements in brain activity patterns. Additional smaller studies and case series have reported similar findings, and several clinical trials are ongoing around the world to further evaluate HBOT for post-COVID conditions.
In the 2022 Scientific Reports randomized controlled trial, participants received 40 sessions of HBOT over approximately two months, with five sessions per week. Each session lasted 90 minutes at 2.0 ATA with air breaks. This protocol was designed to provide sufficient exposure for measurable biological and clinical changes. Other research groups have explored different protocols, but the 40-session model is the most well-studied in published literature for long COVID. The optimal number of sessions may vary by individual, and ongoing research aims to refine treatment protocols. Any HBOT protocol should be discussed with a qualified healthcare provider.
HBOT has a well-established safety profile when administered in FDA-cleared chambers following proper protocols. In the published long COVID clinical trials, HBOT was well tolerated with minimal adverse effects. The most common side effects are mild ear pressure during pressurization and occasional temporary changes in vision, both of which typically resolve on their own. OxyHealth chambers are FDA 510(k)-cleared, built to ASME PVHO-1 standards, and manufactured under ISO 13485 quality management systems. As with any medical intervention, individuals should consult their healthcare provider before starting HBOT, especially if they have active respiratory infections or other contraindications.
OxyHealth manufactures FDA-cleared portable hyperbaric chambers designed for safe home use, including the Vitaeris 320 and Respiro 270. Home chambers operate at 1.3 ATA, which is classified as mild hyperbaric therapy. The published clinical research on HBOT for long COVID has primarily used higher-pressure protocols at 2.0 ATA in clinical settings. Some individuals choose home chambers as part of a broader wellness approach, as the convenience of daily access may support more consistent use. For those interested in higher-pressure protocols, OxyHealth clinical chambers such as the Fortius 420 are available for medical facilities. Consult with a healthcare provider to determine the most appropriate approach for your situation.
Researchers are studying HBOT across a range of persistent post-COVID symptoms. The 2022 Scientific Reports trial specifically measured and reported improvements in cognitive function (attention, executive function, memory), fatigue and energy levels, sleep quality, and pain. Other research groups are investigating HBOT for exercise intolerance, shortness of breath, neuroinflammation, and overall quality of life in long COVID patients. Brain imaging studies within the research have also evaluated changes in cerebral blood flow and brain microstructure following HBOT. These areas of investigation reflect the diverse and complex nature of long COVID.
Standard supplemental oxygen delivers additional oxygen at normal atmospheric pressure, which increases the oxygen carried by hemoglobin in red blood cells. HBOT goes further by combining concentrated oxygen with elevated atmospheric pressure inside a sealed chamber. Based on Henry's Law of physics, this combination forces significantly more oxygen to dissolve directly into blood plasma, cerebrospinal fluid, and other body fluids. This dissolved oxygen can reach areas of the body that red blood cells may not easily access, particularly tissues with compromised or damaged microvasculature. Researchers hypothesize that this enhanced oxygen delivery mechanism is what makes HBOT particularly relevant for conditions like long COVID, where microvascular damage may play a role in persistent symptoms.
Learn More